Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer's disease: High‐resolution fast spin‐echo T 1‐weighted imaging
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aim: Neuronal degeneration in the locus coeruleus occurs in the early phase of A lzheimer's disease, similar to mild cognitive impairment. The locus coeruleus produces norepinephrine, a deficiency of which causes both memory disturbance and psychological symptoms. Thus, we evaluated signal alterations in the locus coeruleus of patients with A lzheimer's disease and mild cognitive impairment using a high‐resolution fast spin‐echo T 1‐weighted imaging. Methods: A total of 22 patients with A lzheimer's disease, 47 patients with mild cognitive impairment and 26 healthy controls were prospectively examined by high‐resolution fast spin‐echo T 1‐weighted imaging at 3 T esla. Signal intensities in the locus coeruleus were manually measured and expressed relative to those in the adjacent white matter structures as contrast ratios. Results: Locus coeruleus contrast ratios were significantly reduced in patient groups with A lzheimer's disease, mild cognitive impairment that converted to A lzheimer's disease and mild cognitive impairment that did not convert to A lzheimer's disease (1.80–16.09% [median, 9.30%], 3.45–14.84% [median 6.87%] and 3.01–19.19% [median 7.72%], respectively) compared with the healthy control group (6.24–20.94% [median 14.35%]; P < 0.0001). The sensitivity and specificity for discriminating these diseases were 85.0% and 69.2%, respectively, which suggests that this measurement can be carried out reliably. There was no significant difference in the locus coeruleus contrast ratios among the A lzheimer's disease, mild cognitive impairment‐converted and mild cognitive impairment‐non‐converted groups. Conclusions: High‐resolution fast spin‐echo T 1‐weighted imaging can show signal attenuation in the locus coeruleus of patients with A lzheimer's disease or with mild cognitive impairment whose pathology may or may not eventually convert to A lzheimer's disease. Geriatr Gerontol Int 2015; 15: 334–340.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
Whitwell, J. L., Przybelski, S. A., Weigand, S. D., Knopman, D. S., Boeve, B. F., Petersen, R. C., & Jack, C. R. (2007) · Brain · doi:10.1093/brain/awm112 · Cited by 607
Sasaki, M., Shibata, E., Tohyama, K., Takahashi, J., Otsuka, K., Tsuchiya, K., Takahashi, S., Ehara, S., Terayama, Y., & Sakai, A. (2006) · Neuroreport · doi:10.1097/01.wnr.0000227984.84927.a7 · Cited by 496
Self-citationGrudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396
Neuropathology of mild cognitive impairment
Saito, Y., & Murayama, S. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00806.x · Cited by 92
Cited by
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467
“Most relevant prior studies have either focused on the most severe cases with TPSD or have investigated the associations between medial temporal lobe or brainstem tau pathology related to AD [5, 6, 11, 12, 19, 48, 49, 55, 56, 79, 133, 134, 144].”
BackgroundThe Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain
Mather, M., & Harley, C. W. (2016) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2016.01.001 · Cited by 492
O'Dell, T. J., Connor, S. A., Guglietta, R., & Nguyen, P. V. (2015) · Learning & Memory · doi:10.1101/lm.031088.113 · Cited by 163
“…degeneration of noradrenergic neurons in the locus coeruleus occurs early in Alzheimer’s disease (AD) (Szot et al. 2006; Grudzien et al. 2007; Takahashi et al. 2015) and soluble oligomers of amyloid beta (Ab) proteins can induce a rapid down-regulation and internalization of b2-ARs (Wang et…”
BackgroundSearching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18
Metadata
- Authors
- Takahashi, J., Shibata, T., Sasaki, M., Kudo, M., Yanezawa, H., Obara, S., Kudo, K., Ito, K., Yamashita, F., & Terayama, Y.
- Venue
- Geriatrics & Gerontology International
- Publisher
- Wiley
- Published
- 2014-03-25
- Volume
- 15
- Issue
- 3
- Pages
- 334-340
- ISSN
- 1444-1586 (ISSN-L)
- 1447-0594
- OpenAlex
- W1489255022
- Cited by
- 105
- References
- 11
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.